Compare Electronic Arts Inc. (EA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Electronic Arts Inc. vs BIO-TECHNE Corp — how do they compare? Electronic Arts Inc. trades at $207.51 (market cap $51.97B), while BIO-TECHNE Corp trades at $71.75 (market cap $11.14B). The key difference: Electronic Arts Inc. is far larger — about 4.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.45%). Which is the better fit depends on your goals.
| EA | TECH | |
|---|---|---|
Market Cap | $51.97B | $11.14B |
Sector | Technology | Health |
52-Week High | $207.27 | $71.48 |
52-Week Low | $147.79 | $43.31 |
Enterprise Value | $50.54B | $11.22B |
Dividend Yield | 0.37% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Electronic Arts (EA) trades at $207.31, up 0.32% on the day, with a bullish technical signal from moving averages and strong support at $205. The company reported Q4 2025 EPS beat but Q1 2026 miss, with revenue stable around $7.5B and a net income margin of 11.78%. Recent launches like EA SPORTS College Football 27 and UFC 6 highlight ongoing product momentum, while a potential $55B acquisition by Saudi investors adds strategic intrigue.
Outlook remains mixed: high valuation ratios (P/E 59.05) suggest premium pricing, but robust cash flow and dividend payments support shareholder returns. Key risks include earnings volatility and competitive pressures in gaming. Analyst consensus leans Hold (56.06%), indicating cautious optimism amid execution uncertainties.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
